Ørsted’s Strategic Asset Sales Drastically Reduce Debt Burden
Ørsted’s major asset sales slash debt, leading Barclays to upgrade its rating. Analysts forecast rising EBITDA as the…
Novo Nordisk’s Strategic Pivot Faces Crucial First-Quarter Test
Novo Nordisk shares down 20% YTD as it faces new oral obesity drug competition from Eli Lilly and…
AI and Aggressive Pricing in a Shifting Market
Novo Nordisk slashes US Wegovy HD price to $399/month, partners with OpenAI for AI integration, and faces generic…
Saudi Cash and Greenland’s Clock Drive Value
European Lithium’s fate hinges on a Greenland permit for Tanbreez rare earths project, despite a strong cash position…
Saudi Cash and Greenland’s Clock Drive Value
European Lithium’s fate hinges on a Greenland permit for Tanbreez rare earths project, despite a strong cash position…
Cash and Greenland Take Center Stage
European Lithium boasts AUD 322M cash, launches buyback. Greenland rare earths project advances with high-grade results, while flagship…
Cash and Greenland Take Center Stage
European Lithium boasts AUD 322M cash, launches buyback. Greenland rare earths project advances with high-grade results, while flagship…
Novo Nordisk Navigates Pricing Pressures with Strategic Pivot
Novo Nordisk slashes prices in some markets and launches Wegovy subscriptions as new clinical data shows edge over…
Novo Nordisk Navigates Pricing Pressures with Strategic Pivot
Novo Nordisk slashes prices in some markets and launches Wegovy subscriptions as new clinical data shows edge over…
Ørsted’s Strategic Asset Sales Drastically Reduce Debt Burden
Ørsted’s major asset sales slash debt, leading Barclays to upgrade its rating. Analysts forecast rising EBITDA as the…
Novo Nordisk Charts a New Strategic Direction Amid Challenges
Novo Nordisk navigates FDA warnings, partners with Hims & Hers for digital sales, and expands in South America…
Hims & Hers Stock Soars on Strategic Pivot with Novo Nordisk
Hims & Hers settles patent litigation, will now sell Novo Nordisk’s Ozempic and Wegovy. The telehealth firm forecasts…